Cover Image
市場調查報告書

思覺失調症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

Schizophrenia: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365213
出版日期 內容資訊 英文 284 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
思覺失調症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 Schizophrenia: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 284 Pages
簡介

在思覺失調症的治療藥市場有龐大的未滿足需求存在,不過,預計未來將有巨大市場機會並市場迅速成長。

本報告提供思覺失調症的已上市/臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,市場主要推動因素,及目前治療方法與其問題點,目前的有力品牌藥,在臨床實驗的最後階段的開發中產品一覽,其中特別有前途的產品等相關調查。

市場預測:思覺失調症

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Abilify (Aripiprazole)
  • Abilify Maintena (Aripiprazole)
  • ALKS 3831 (olanzapine/samidorphan)
  • Aristada (Aripiprazoleraurokishiru)
  • Invega Sustenna/Trinza (paliperidone palmitate)
  • Latuda (Lurasidone)
  • Lonasen (blonanserin)
  • Rexulti (brexpiprazole)
  • Risperdal Consta (risperidone)
  • Saphris (asenapine)
  • Seroquel/Seroquel XR (富馬酸Quetiapine)
  • Vraylar (鉀肥普拉琴酒)
  • 一次調查技術

治療方法:思覺失調症

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢
  • 思覺失調症相關的未滿足需求

流行病學:思覺失調症

  • 摘要整理
  • 資訊來源、分析方法
  • 市場預測
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:思覺失調症

  • 摘要整理
  • 產品概要
  • 產品簡介:Abilify
  • 產品簡介:Abilify Maintena
  • 產品簡介:Aristada
  • 產品簡介:Invega Sustenna/Trinza
  • 產品簡介:Latuda
  • 產品簡介:Rexulti
  • 產品簡介:Risperdal Consta
  • 產品簡介:Saphris
  • 產品簡介:Seroquel/Seroquel XR
  • 產品簡介:Vraylar
  • 產品簡介:Zyprexa

開發中產品:思覺失調症

  • 摘要整理
  • 臨床實驗開發平台概要
  • 治療方法比較
  • 最近臨床實驗中止的藥物
  • 產品簡介 (最後階段):ALKS 3831
  • 產品簡介 (最後階段):ITI-007

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC4983

Schizophrenia's unmet needs can be turned into key commercial opportunities to drive the growth of the market.

This report addresses the following questions:

  • What will be the key growth drivers of the schizophrenia market?
  • Which will be the new leading brands in schizophrenia, now that former market-leader Abilify faces generic competition?
  • What are the main trends in late-stage drug development for schizophrenia, and which candidates have shown promise in clinical trials?
  • Which are the most clinically and commercially attractive brands in the schizophrenia market?
  • How are schizophrenia patients currently managed, and which are the key treatment challenges they encounter?

TABLE OF CONTENTS

FORECAST: SCHIZOPHRENIA

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Methodology and Market Definition
  • 4. Abilify (aripiprazole)
  • 5. Abilify Maintena (aripiprazole)
  • 6. ALKS 3831 (olanzapine/samidorphan)
  • 7. Aristada (aripiprazole lauroxil)
  • 8. Invega Sustenna/Trinza (paliperidone palmitate)
  • 9. Latuda (lurasidone)
  • 10. Lonasen (blonanserin)
  • 11. Rexulti (brexpiprazole)
  • 12. Risperdal Consta (risperidone)
  • 13. Saphris (asenapine)
  • 14. Seroquel/Seroquel XR (quetiapine fumarate)
  • 15. Vraylar (cariprazine)
  • 16. Primary Research Methodology

TREATMENT: SCHIZOPHRENIA

  • 17. Executive Summary
  • 18. Primary Research Methodology
  • 19. Disease Definition and Diagnosis
  • 20. Patient Segmentation
  • 21. Country Treatment Trees
  • 22. Current Treatment Options
  • 23. Prescribing Trends
  • 24. Unmet Needs in Schizophrenia

EPIDEMIOLOGY: SCHIZOPHRENIA

  • 25. Executive Summary
  • 26. Sources and Methodology
  • 27. Forecast
  • 28. Epidemiologist Insight
  • 29. Strengths and Limitations

MARKETED DRUGS: SCHIZOPHRENIA

  • 30. Executive Summary
  • 31. Product Overview
  • 32. Product profile: Abilify
  • 33. Product profile: Abilify Maintena
  • 34. Product profile: Aristada
  • 35. Product profile: Invega Sustenna/Trinza
  • 36. Product profile: Latuda
  • 37. Product profile: Rexulti
  • 38. Product profile: Risperdal Consta
  • 39. Product profile: Saphris
  • 40. Product profile: Seroquel/Seroquel XR
  • 41. Product profile: Vraylar
  • 42. Product profile: Zyprexa

PIPELINE: SCHIZOPHRENIA

  • 43. Executive Summary
  • 44. Clinical Pipeline Overview
  • 45. Comparator Therapy
  • 46. Recently Discontinued Drugs
  • 47. Product profile (late stage): ALKS 3831
  • 48. Product profile (late stage): ITI-007
Back to Top